Highlights Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-13 EDT			5-day change	1st Jan Change
8.45 ^USD	-8.75%		-8.35%	+130.87%

05-13	Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating	MT
05-08	Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder	03-08	CI
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump	03-07	MT
Mind Medicine Inc. Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data from Phase 2B Study of MM120 for Generalized Anxiety Disorder	03-07	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mind Medicine Inc. Provides Anticipated Production Milestones for 2024	01-08	CI
Mind Medicine Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder	12-14	CI
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Mind Medicine Inc. Completes Enrollment of Phase 2A Trial of Mm-120 in Adults with Attention-Deficit/Hyperactivity Disorder	23-10-24	CI
Mind Medicine Completes Enrollment and Dosing in Study Mmed008	23-09-12	CI
Mind Medicine Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Mind Medicine Inc. Provides Overview of Clinical Progress	23-06-20	CI
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy	23-05-25	CI
Mind Medicine Inc. Enters into Phase 2b Clinical Trial Evaluating MM-120 (lysergide D-Tartrate) for GAD	23-05-17	CI
Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Mind Medicine Inc. Announces Positive Data from Phase 2 Trial of Lysergide in Major Depressive Disorder	23-04-14	CI
Mind Medicine Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Trippy Trading: Top Psychedelic Stocks For 2023	23-01-17	AQ
Mind Medicine Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mind Medicine (MindMed) Inc.

Equities

MNMD

CA60255C8850

Highlights

Filters